



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

Chemical stability and physical compatibility of meropenem in admixtures for continuous and extended intravenous infusions



Sara Giménez-Giner^a, Antoni Llopis-Alemany^a, Begoña Porta-Oltra^a, Pilar Llopis-Salvia^a,
Mónica Climente-Martí^a, María Amparo Martínez-Gómez^{b,*}

^a Department of Pharmacy, Doctor Peset University Hospital, Valencia, Spain

^b Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, (FISABIO), Valencia, Spain

ARTICLE INFO

Article history:

Received 31 May 2022

Accepted 14 July 2022

Available online 9 September 2022

Keywords:

Compatibility

Stability

Meropenem

Infusor

ABSTRACT

Introduction: Prolonged intravenous infusion of beta-lactams increase the clinical cure rate compared to conventional administration in critical or septic patients. This study aimed to determine chemical stability and physical compatibility of meropenem at conditions used in clinical practice to evaluate the stability of the preparation during its administration and the possibility of anticipated preparation.

Methods: Admixtures in study were: (i) meropenem 6 g in 0.9% sodium chloride (NS) in infusor of 2 mL/h 50 mL or 10 mL/h 240 mL; (ii) meropenem 1 or 2 g in NS in infusion bag of 250 mL. Temperatures of study were: (i) infusor: 4.5 °C, 32 °C or 12 h at 4.5 °C followed by 32 °C; (ii) Infusion bag: 4.5 °C, 24.5 °C or 6 h at 4.5 °C followed by 24.5 °C. Time of study was 5–6 days in infusor and 1 day in infusion bag. Chemical stability was evaluated by high performance liquid chromatography and physical compatibility by measuring pH and visual inspection.

Results: Chemical stability and physical compatibility of meropenem in admixtures in infusors were reduced at high meropenem concentration and high temperature. Admixtures in infusion bag show chemical stability and physical compatibility for at least 1 day.

Conclusion: Administration of meropenem 6 g in infusion of 24 h in 240 mL of 0.9% NaCl in infusor of 10 mL/h could be possible if the admixture is infused at 4.5 °C. Extended infusion of meropenem 1 or 2 g in 0.9% NaCl in infusion bag (250 mL) in 3–4 h is also feasible. Anticipated preparation of the admixtures in infusion bag is possible with a stability of 24 h.

© 2022 Sociedad Española de

Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Estabilidad química y compatibilidad física de meropenem en mezclas para infusión intravenosa continua y extendida

RESUMEN

Introducción: La infusión intravenosa prolongada de beta-lactámicos aumenta la velocidad de curación clínica comparada con la administración convencional en pacientes críticos o sépticos. Este estudio tiene como objetivo determinar la estabilidad química y la compatibilidad física de meropenem en condiciones utilizadas en la práctica clínica para evaluar la estabilidad de la preparación durante su administración y la posibilidad de la preparación anticipada.

Métodos: Las mezclas en estudio fueron: (I) meropenem 6g en cloruro sódico 0,9% (SN) en infusor de 2mL/h 50 mL o 10mL/h 240mL; (iii) meropenem 1 o 2g en SN en bolsa de infusión de 250mL. Las temperaturas de estudio fueron: (i) infusor: 4,5 °C, 32 °C o 12h a 4,5 °C seguido de 32 °C; (ii) bolsa de infusión: 4,5 °C, 24,5 °C o 6h a 4,5 °C seguido de 24,5 °C. El tiempo de estudio fue de 5–6 días en infusor y 1 día en bolsa de infusión. Se evaluó la estabilidad química mediante cromatografía líquida de alta resolución y la compatibilidad física por medida de pH e inspección visual.

Palabras clave:

Compatibilidad

Estabilidad

Meropenem

Infusor

* Corresponding author.

E-mail address: martinez_margoma@gva.es (M.A. Martínez-Gómez).

Resultados: La estabilidad química y la compatibilidad física de meropenem en las mezclas en infusores disminuyeron al aumentar la concentración de meropenem y la temperatura. Las mezclas en bolsas de infusión mostraron estabilidad química y compatibilidad física durante al menos 1 día.

Conclusión: La administración de meropenem 6g en infusión de 24h en 240 mL de cloruro sódico 0,9% en infusor de 10ml/h podría ser posible si la mezcla es administrada a 4,5°C. La infusión extendida de 1 o 2g en cloruro sódico 0,9% en bolsa de infusión (250 mL) en 3–4h es también viable. Puede realizarse la preparación anticipada de mezclas de meropenem en bolsas de infusión con una estabilidad de 1 día.

© 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Meropenem is a broad-spectrum antibiotic with bactericidal activity against Gram positive and negative bacteria. Meropenem acts by inhibiting the synthesis of the bacterial cell wall, and it is indicated in the treatment of serious lung, urinary, intrabdominal, skin and soft tissue infections or meningitis, with dosage ranging from 1 g every 8 h to 2 g in lung infections associated with cystic fibrosis or acute bacterial meningitis.¹

The efficacy of meropenem is correlated with the time that plasma concentrations exceed the minimum inhibitory concentration of the pathogen ($T > \text{MIC}$).² In carbapenems, the PK-PD objective is to achieve $T > \text{MIC}$ during approximately 40% of the dosing interval,¹ though this objective has not been established in the clinical setting and studies in critically ill patients point to better clinical and microbiological results with 100% $T > \text{MIC}$.^{3,4} The carbapenem MIC breakpoint, according to the international reference organizations, will determine the sensitivity or resistance of the microorganism to the antibacterial. In order to achieve clinical cure of serious infections and prevent antimicrobial resistance, dose optimization is needed.⁵

Meropenem 1 g is usually administered by intermittent infusion (II) over approximately 30 min, producing a peak plasma concentration of 50–60 mg/L, which drops to 0.25 mg/L after 8 h.¹ Several studies evidence that prolonged infusions of meropenem, including extended infusion (EI) and continuous infusion (CI), provide greater likelihood of reaching the $T > \text{MIC}$ target than standard dosage forms.^{6–9} CI would ideally achieve a higher $T > \text{MIC}$, but it has drawbacks such as permanent attachment to the line, Y-site incompatibilities, and mainly stability problems associated with carbapenems.¹⁰ However, EI of 1 or 2 g of meropenem each 8 h stands as an effective alternative since it increases the $T > \text{MIC}$, avoiding the disadvantages associated with the CI. Jaruratanasirikul et al.¹¹ point out that EI would achieve the PK-PD objective of 40% $T > \text{MIC}$ with a likelihood of 90% compared to 79% with II for doses of 0.5 g/8 h ($\text{MIC} \leq 4 \text{ mg/L}$), 1 g/8 h ($\text{MIC} \leq 8 \text{ mg/L}$) and 2 g/8 h ($\text{MIC} \leq 16 \text{ mg/L}$).

To ensure that patients receive sufficient meropenem to achieve cure while avoiding exposure to toxic degradation products, chemical stability and physical compatibility of meropenem should be maintained throughout the period of administration. Stability data available until now indicate that meropenem in 0.9% sodium chloride (NS) at concentrations ranged from 4 to 20 mg/mL is stable for 3–7 days at 5 °C in elastomeric infusion devices for CI^{12,13} and that meropenem 1 or 2 g in 100 mL with NS (10 and 20 mg/mL, respectively) is stable for 5 days at 5 °C and 10 h at 25 °C in infusion bags for EI.^{12–14}

The objective of the present study is to determine the chemical stability and physical compatibility of meropenem in elastomeric infusion devices and infusion bags at concentrations used in clinical practice (25 and 120 mg/mL in infusors; 4 and 8 mg/mL in infusion bags) at different temperatures (4.5, 24.5 or 32 °C), in order to evaluate the stability of the preparation during its administration by

CI or EI and the possibility of anticipated preparation of admixtures.

Methods

Reagents and materials

As reagents, meropenem 1000 mg powder for injection (Aurovitas Spain, Barcelona, Spain), NS in Viaflo® infusion bag (made of polyethylene, polyamide and polypropilen) of 50 or 250 mL (Baxter, Barcelona, Spain), sterile water (API) for injection (B. Braun, Barcelona, Spain), acetonitrile (Scharlab, Barcelona, Spain) and sodium dihydrogen phosphate (NaH_2PO_4 ; Panreac, Barcelona, Spain) were acquired.

Singleday® 2 mL/h 50 mL and Folfusor® LV 10 mL/h 240 mL (Baxter, Barcelona, Spain) elastomeric infusion devices (made of polyisoprene) and light protection bags (Diffuplast, Italy) were used.

Admixtures

Admixtures were prepared by duplicate following Good Manufacturing Practice (GMP)¹⁵, being 24 the total number of admixtures. Table 1 shows dose, volume and container of the admixtures. To prepare them, meropenem powder was reconstituted with API and diluted to the corresponding volume with NS. All admixtures were introduced in light protection bags.

Stability studies

Chemical stability and physical compatibility of meropenem were evaluated at different concentrations and temperatures (Table 1). Admixtures in infusors were stored at 32 °C, since it is the physiological temperature reached by the infusor during its administration,¹⁶ and at 4.5 °C because previous studies indicate that meropenem is more stable under refrigeration than at high temperatures.¹⁴ Admixtures in infusion bags were also stored at 4.5 °C and at 24.5 °C, as room temperature during administration. The possibility of anticipated preparation was evaluated by storing admixtures at 4.5 °C followed by 32 °C for infusors or 24.5 °C for infusion bags; time of refrigeration was greater in admixtures in infusors (12 h) than in infusion bags (6 h) since its preparation is more complex, takes more time and due to the high workload of nursing staff, it can be prepared during a 12-h shift. Time of study was 5–6 days for infusors and 1 day for infusion bags; the fact of evaluating chemical stability and physical compatibility for more than 1 day in infusors is that its cost is highest and the preparation is most complex so, in case of not administering the infuser to the patient, it can be reused.

Chemical stability of meropenem in each admixture was determined by measuring its concentration by high performance liquid chromatography (HPLC) in an aliquot of 1 mL extracted at different sampling times: just after preparation ($t = 0 \text{ h}$) and at 2, 4, 8, 12

Table 1

Dose, volume, container, temperature and time of the study of the admixtures of meropenem.

AD	Dose (g)	V (mL)	Container	T (°C)	t (days)
1–2	6	50	Singleday® 2 mL/h 50 mL	4.5	5
3–4	6	50	Singleday® 2 mL/h 50 mL	32	5
5–6	6	50	Singleday® 2 mL/h 50 mL	12 h at 4.5 °C + 32 °C	6
7–8	6	240	Folfusor® LV 10 mL/h 240 mL	4.5	5
9–10	6	240	Folfusor® LV 10 mL/h 240 mL	32	5
11–12	6	240	Folfusor® LV 10 mL/h 240 mL	12 h at 4.5 °C + 32 °C	6
13–14	1	250	Viaflo®	4.5	1
15–16	1	250	Viaflo®	24.5	1
17–18	1	250	Viaflo®	6 h at 4.5 °C + 24.5 °C	1
19–20	2	250	Viaflo®	4.5	1
21–22	2	250	Viaflo®	24.5	1
23–24	2	250	Viaflo®	6 h at 4.5 °C + 24.5 °C	1

AD: admixture; V: final volume; T: temperature; t: time of study.

and 24 h and then every 24 h for 5–6 days for admixtures stored in infusors and at 2, 4, 6, 9, 12, 14 and 24 h for admixtures in infusion bags.

An Agilent Technologies 1100 HPLC system (Agilent Technologies Inc., Waldbronn, Karlsruhe, Germany) with a diode array detector was used for the analysis. The HPLC method was modified from Foy et al.¹⁷ Chromatographic separations were achieved on a reversed phase column C18® (150 mm × 4.6 mm inner diameter; 5 µm) with a gradient of mobile phase containing 0.01 M NaH₂PO₄ pH 2 and acetonitrile ($t = 0$ min, 93:7, v/v; $t = 6$ min, 88:12, v/v; $t = 16$ min, 51:49, v/v, respectively) at a flow rate of 0.8 mL/min. Column temperature was 25 °C and injection volume, 5 µL; wavelength was 298 nm and time of analysis, 17 min. Chromatographic method was previously validated according to the International Conference on Harmonization (ICH) guidelines¹⁸ and was adequate to determine meropenem in admixtures.

The remaining concentration of meropenem (%RC) at each sampling time was expressed as the mean percentage and standard deviation (SD) of the initial concentration (after preparation); the initial concentration was expressed as 100%. The stability of a solution for infusion is maintained when the %RC remains >90% throughout the infusion period.^{19,20} So, the parameter used to define chemical stability was T_{90} , time at which %RC was 90%.

The pair data concentration-time were adjusted, if possible, to a zero- (Eq. (1)) or first-order kinetic equation (Eq. (2)). T_{90} was estimated by considering the time at which the 95% one-sided confidence limit for the mean curve intersects 90% of the initial concentration of meropenem:

$$C = C_0 - K_0 t \quad (1)$$

$$\ln C = \ln C_0 - K_1 t \quad (2)$$

being C , meropenem concentration at a specific sampling time; C_0 , meropenem concentration at $t = 0$; K_0 , zero-order degradation rate constant and K_1 , first-order degradation rate constant; t , sampling time.

Physical compatibility of each admixture was evaluated at each sampling time by measuring, in an extracted aliquot of 5 mL: (i) pH, with glass electrode and pH-meter (model 3510, Jenway, UK); incompatibility if variation of pH is >5%; (ii) color changes, cloudiness (turbidity) and/or precipitation, measured by visual inspection; incompatibility if some of these parameters appear.

Results

Table 2 shows chemical stability and physical compatibility parameters for all the admixtures: (a) the average of %RC at the end of the study and the parameter T_{90} ; (b) the initial value of pH, time at which variation of pH was >5% and time at which the color

of admixture changed; (c) expiration time, by considering chemical stability and physical compatibility.

As regards admixtures in infusors (admixtures 1–12), the increase in temperature from 4.5 °C to 32 °C lead to a 64% decrease in %RC at the end of the study and significant decreases in T_{90} from 5 days to 14 h in Singleday® 2 mL/h 50 mL (120 mg/mL) and from 4 days to 7 h in Folfusor® LV 10 mL/h 240 mL (25 mg/mL). Similar %RC and T_{90} values were obtained for admixtures stored at 32 °C, with and without pre-cooling. In admixtures with a concentration of meropenem of 120 mg/mL (admixtures 1–4), there were variations of pH > 5% from day 5 at 4.5 and 32 °C and visual color changes were observed earliest that in admixtures with low meropenem concentration (admixtures 7–12). So, expiration time was shorter when increasing the concentration of meropenem.

In admixtures stored in Viaflo® (admixtures 13–24), %RC was ≥90% at the end of the study (1 day). Variations of pH were <5% in all cases and visual color changes were not observed. So, expiration time was at least 1 day, since it is the time of the study.

Table 3 shows the kinetic parameters for meropenem degradation and estimated T_{90} values.

Discussion

Previous studies indicate that the stability of meropenem depends on the diluent, concentration, temperature and pH.^{17,21} NS is usually used as diluent since it improves stability of meropenem compared to other diluents such as glucose 5% or 10%.¹³ Stability of meropenem in NS solution decreases with increasing concentration of meropenem^{17,21} and with increasing temperatures,^{14,17,21} being stable for a longer time under refrigeration and degrading more quickly at temperatures upper than 35 °C.^{17,21,22} In our study, there were not statistically significant differences in %RC and T_{90} between admixtures in infusors with different meropenem concentration (admixtures 1–6, 120 mg/mL; admixtures 7–12, 25 mg/mL) but physical compatibility and consequently, expiration time were reduced at high meropenem concentration and at high temperature (32 °C). The observed color changes could be a consequence of the degradation of meropenem by hydrolysis of the beta-lactam ring,¹⁹ favored by high concentration and temperature; when color changes, it is recommended not to administer admixtures since physical incompatibility is usually related to loss of potency and increase in toxicity.

So, the only admixture that can be administered in CI of 24 h is meropenem 6 g in 240 mL of NS in Folfusor® LV 10 mL/h 240 mL as long as it is infused at 4.5 °C, being expiration time of 4 days. This admixture becomes a possible alternative in Home Care Units, where EI (administration every 8 h and drug withdrawal after 3–4 h) is not a viable option. Several studies have proposed different ways to maintain infusors under refrigeration during its admin-

Table 2

Chemical stability and physical compatibility parameters of meropenem in admixtures at the end of the study.

AD	Chemical stability		Physical compatibility			Expiration time
	%RC (%)	T ₉₀	pH ₀	pH variation >5%	Color change	
1–2	90.9 ± 1.6	5 d	8.05 ± 0.1	5 d	4 h	4 h
3–4	32.8 ± 0.7	14 h	7.97 ± 0.00	5 d	1 h	1 h
5–6	32.0 ± 1.8	12 h 4.5 °C + 5 h 32 °C	8.1 ± 0.0	–	4 h	4 h
7–8	85.2 ± 1.6	4 d	8.00 ± 0.03	–	4 d	4 d
9–10	31.2 ± 2.3	7 h	8.14 ± 0.10	–	7 h	7 h
11–12	26.1 ± 0.7	12 h 4.5 °C + 2 h 32 °C	7.975 ± 0.007	–	12 h 4.5 °C + 3 h 32 °C	12 h 4.5 °C + 2 h 32 °C
13–14	96.9 ± 0.6	^a	7.17 ± 0.09	–	–	1 d ^b
15–16	90.9 ± 0.8	1 d	7.240 ± 0.014	–	–	1 d
17–18	93.1 ± 0.6	^a	7.245 ± 0.007	–	–	1 d ^b
19–20	93.618 ± 0.014	^a	7.235 ± 0.007	–	–	1 d ^b
21–22	95.6 ± 2.4	^a	7.24 ± 0.00	–	–	1 d ^b
23–24	94.9 ± 0.5	^a	7.25 ± 0.00	–	–	1 d ^b

AD: admixture; %RC: percentage of remaining concentration of meropenem ± standard deviation (%); T₉₀: time at which %RC is 90%; d: day; h: hour; pH₀: initial pH; pH variation, >5%: time at which variation of pH was >5%; color change: time at which color of admixture changed; –: without changes.

^a %RC > 90%.

^b Minimum 1 day.

Table 3

Kinetic parameters for meropenem degradation.

A D	Zero-order			First-order		
	K ₀ × 10 ^{–3} (mg mL ^{–1} h ^{–1})	r ²	T ₉₀	K ₁ × 10 ^{–3} (mg mL ^{–1} h ^{–1})	r ²	T ₉₀
1–2	130.3 ± 15.1	0.6777	4 d	1.12 ± 0.14	0.6935	4 d
3–4	760.7 ± 17.9	0.991	17 h	8.6 ± 0.3	0.991	12 h
5–6	646.3 ± 23.9	0.980	12 h 4.5 °C + 7 h 32 °C	7.5 ± 0.3	0.991	12 h 4.5 °C + 2 h 32 °C
7–8	–	–	–	–	–	–
9–10	176.2 ± 8.9	0.945	15 h	10.4 ± 0.4	0.988	10 h
11–12	294.4 ± 10.9	0.978	12 h 4.5 °C + 6 h 24.5 °C	8.72 ± 0.23	0.996	12 h 4.5 °C

AD: admixture; K₀: zero-order degradation rate constant; K₁: first-order degradation rate constant; r²: regression coefficient, T₉₀: time at which %RC is 90%; –: data could not be adjusted to kinetic equations.

Table 4T₉₀ of admixtures of meropenem in infusion bags at different temperatures and concentrations.

Concentration	Temperature (°C)	Infusion bag	T ₉₀	Ref.
1 g/100 mL	2–8	?	1 d	1
	5	PVC	5 d	23
	25	?	3 h	1
	25	PVC	9–10 h	22
1 g/250 mL	4.5	PE, PA, PP	1 d ^a	–
	24.5	PE, PA, PP	1 d	–
2 g/100 mL	4	PVC	2 d	13
	5	PVC	5 d	23
	21–26	PVC	10 h	13
	25	PVC	5–6 h	22
2 g/250 mL	4.5	PE, PA, PP	1 d ^a	–
	24.5	PE, PA, PP	1 d ^a	–

PE: polyethylene; PA: polyamide; PP: polypropylene; ?: unknown; T₉₀: time at which %RC is 90%; d: days; h: hours; Ref.: reference; –: results obtained in the present study.

^a Minimum 1 day.

istration such as placing the infusors with frozen ice-bricks in a standard carry-bag^{17,21} or in a cassette attached to an infusion pump²²; Grant et al. indicate that it is possible to maintain elastomeric infusion devices at 2–8 °C over 24 h in a cassette between two ice-bricks, which are changed every 8 h, at a room temperature of 20–25 °C.²²

Admixtures containing 1 or 2 g of meropenem in 250 mL of NS in Vialflo® can be used for II (15–30 min) or EI (3–4 h) at 4.5 or 24.5 °C. Table 4 shows T₉₀ of admixtures of 1 or 2 g of meropenem in 100 mL and 250 mL of NS at room temperature or under refrigeration. As

can be observed, increasing the final volume from 100 to 250 mL, chemical stability increases up to 1 day at 24.5 °C, which would allow EI of meropenem 1 or 2 g in 3–4 h.

Consequently, as previous studies have shown in clinical practice,^{24–26} the fact of administering meropenem by CI or EI would increase the clinical cure rate by 30% compared to conventional administration of beta-lactams in critical or septic patients. These results are also supported by meta-analysis in critically ill patients or with infections caused by high MIC pathogens, which indicate higher clinical cure rate and lower mortality.^{27–30}

Finally, the possibility of preparation in advance of admixtures of meropenem in NS in infusors and infusion bags was evaluated. The results obtained in this study indicated that preparation in advance is not possible in infusors for CI since after 12 h stored at 4.5 °C, T₉₀ was 5 h at 32 °C in Singleday® 2 mL/h 50 mL and 2 h in Folfusor® LV 10 mL/h 240 mL, being the time of administration to patients of 24 h. Nevertheless, preparation in advance is viable in Vialflo® if storing the admixture 6 h at 4.5 °C and administering during the following 18 h at 24.5 °C, enough time not only for II (15–30 min) but also for EI (3–4 h).

In conclusion, the administration of meropenem 6 g in perfusion of 24 h in 240 mL of 0.9% NaCl in infusor Folfusor® LV 10 mL/h 240 mL could be possible if the admixture is infused at 4.5 °C. This study also increases chemical stability and physical compatibility of meropenem 1 or 2 g in 0.9% NaCl in Vialflo® infusion bag (250 mL) to 24 h, being between 3 and 10 h^{1,14} in 100 mL; therefore, extended infusion in 3–4 h is also feasible, allowing its use in septic or critically patients or with high MIC Gram negative bacteria in which a higher clinical cure rate has been evidenced. Moreover, anticipated preparation of admixtures of meropenem in Vialflo® is possible, as opposed to its usual method

of preparation at the time of administration because of its short stability.

As a limitation on this study, the results of chemical stability and physical compatibility of meropenem obtained are applicable to infusion bags made of polyethylene, polyamide and polypropylene (Vialfo®) and infusers of polyisoprene (Singeday® and Folfusor®).

Conflict of interest

Authors state no conflict of interest.

References

1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Data sheet; 2020. Available at: <https://cima.aemps.es/cima/dfs/es/ft/74304/FT.74304.pdf> [accessed 01.01.22].
2. Lu C, Zhang Y, Chen M, Zhong P, Chen Y, Yu J, et al. Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery. *Antimicrob Agents Chemother*. 2016;60:6619–25. <http://dx.doi.org/10.1128/AAC.00997-16>.
3. Zhao HY. Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study. *Chin Med J (Engl)*. 2017;130:1139–45. <http://dx.doi.org/10.4103/0366-6999.2058.59>.
4. Roberts JA. DALL: defining antibiotic levels in intensive care unit patients: are current beta-lactam anti-biotic doses sufficient for critically ill patients? *Clin Infect Dis*. 2014;58:1072–83. <http://dx.doi.org/10.1093/cid/ciu027>.
5. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters; 2021. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v.11.0.Breakpoint.Tables.pdf [accessed 01.03.22].
6. Černá Pařízková R, Martinková J, Havel E, Šafránek P, Kaška M, Astapenko D, et al. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. *Crit Care*. 2021;25:251–9. <http://dx.doi.org/10.1186/s13054-021-03680-9>.
7. Benítez-Cano A, Luque S, Sorlí L, Carazo J, Ramos I, Campillo N, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. *Crit Care*. 2020;24:55–68. <http://dx.doi.org/10.1186/s13054-020-2763-4>.
8. Bao H, Lv Y, Wang D, Xue J, Yan Z. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. *Eur J Clin Microbiol Infect Dis*. 2017;36:459–66. <http://dx.doi.org/10.1007/s10096-016-2819-1>.
9. Zhenwei Y, Xiaoping P, Xuqi W, Chunlei S, Saiping J. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. *PLoS One*. 2018;13:e0201667. <http://dx.doi.org/10.1371/journal.pone.0201667>.
10. Fawaz S. Stability of meropenem after reconstitution for administration by prolonged infusion. *Hosp Pharm*. 2019;54:190–6. <http://dx.doi.org/10.1177/0018578718779009>.
11. Jaruratanasirikul S. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. *Antimicrob Agents Chemother*. 2015;59:2995–3001. <http://dx.doi.org/10.1128/AAC.04166-14>.
12. Smith DL, Bauer SM, Nicolau DP. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. *Am J Health Syst Pharm*. 2004;61:1682–5. <http://dx.doi.org/10.1093/ajhp/61.16.1682>.
13. www.stabilis.org; 2022 [accessed 01.03.22].
14. Katip W, Wientong P, Sornsuvit C. The stability of generic meropenem in tropical countries. *Int J Pharm Pharm Sci*. 2015;7:236–8.
15. Good Manufacturing Practice. European Medicines Agency. Available at: <https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice> [accessed 01.03.22].
16. Choi J, Loftness V. Investigation of human body skin temperatures as a bio-signal to indicate overall thermal sensations. *Build Environ*. 2012;58:258–69. <http://dx.doi.org/10.1016/j.buildenv.2012.07.003>.
17. Foy F, Luna G, Martinez J, Nizich Z, Seet J, Lie K, et al. An investigation of the stability of meropenem in elastomeric infusion devices. *Drug Des Devel Ther*. 2019;13:2655–65. <http://dx.doi.org/10.2147/DDDT.S212052>.
18. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1); 1994. Available at: <https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf> [accessed 03.01.22].
19. The United States Pharmacopeia (USP). General Chapter 797. Pharmaceutical compounding: sterile preparations; 2015. Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-gc-797-proposed-revisions-sep-2015.pdf [accessed 01.03.22].
20. The Spanish National Health Service. Ministry of Health, Social Services and Equality. Guide to good practices in preparing medicines in hospital pharmacy services; 2014. Available at: <https://www.msbs.gob.es/profesionales/farmacia/documentacion.htm> [accessed 05.03.22].
21. Manning L, Wright C, Ingram PR, Whitmore TJ, Heath CH, Manson I, et al. Continuous infusion of meropenem in ambulatory care: clinical efficacy, safety and stability. *PLoS One*. 2014;9:e102023. <http://dx.doi.org/10.1371/journal.pone.0102023>.
22. Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R. Stability of meropenem in a portable infusion device in a cold pouch. *Am J Health Syst Pharm*. 2000;57:992–5. <http://dx.doi.org/10.1093/ajhp/57.10.992>.
23. Fawaz S, Stephen B, Whitney L, Swinden J, Nabhani-Gebara S. Stability of meropenem after reconstitution for administration by prolonged infusion. *Hosp Pharm*. 2019;54:190–6. <http://dx.doi.org/10.1177/0018578718779009>.
24. Dulhunty JM. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clin Infect Dis*. 2013;56:236–44. <http://dx.doi.org/10.1093/cid/cis856>.
25. Ahmed N, Jen SP, Altshuler D, Papadopoulos J, Pham VP, Dubrovskaya Y. Evaluation of meropenem extended versus intermittent infusion dosing protocol in critically ill patients. *J Intensive Care Med*. 2020;35:763–71. <http://dx.doi.org/10.1177/0885066618784264>.
26. Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALL) cohort. *J Antimicrob Chemother*. 2016;71:196–207. <http://dx.doi.org/10.1093/jac/ckv288>.
27. Lal A. Prolonged versus intermittent infusion of beta-lactams for the treatment of nosocomial pneumonia: a meta-analysis. *Infect Chemother*. 2016;48:81–90. <http://dx.doi.org/10.3947/ic.2016.48.2.81>.
28. Vardakas KZ. Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. *Lancet Infect Dis*. 2018;18:108–20. [http://dx.doi.org/10.1016/S1473-3099\(17\)30615-1](http://dx.doi.org/10.1016/S1473-3099(17)30615-1).
29. Yu Z. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. *PLoS One*. 2018;13:e0201667. <http://dx.doi.org/10.1371/journal.pone.0201667>.
30. Chen P. Clinical outcomes of continuous vs intermittent meropenem infusion for the treatment of sepsis: a systematic review and meta-analysis. *Adv Clin Exp Med*. 2020;29:993–1000. <http://dx.doi.org/10.17219/acem/121934>.